BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;10:13. [PMID: 24088261 DOI: 10.1186/1559-0275-10-13] [Cited by in Crossref: 244] [Cited by in F6Publishing: 200] [Article Influence: 27.1] [Reference Citation Analysis]
Number Citing Articles
1 Tran WT, Lu FI, Salgado R. Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer. Expert Rev Anticancer Ther 2021;:1-3. [PMID: 34236013 DOI: 10.1080/14737140.2021.1953987] [Reference Citation Analysis]
2 Neumeister VM, Juhl H. Tumor Pre-Analytics in Molecular Pathology: Impact on Protein Expression and Analysis. Curr Pathobiol Rep 2018;6:265-74. [PMID: 30595971 DOI: 10.1007/s40139-018-0179-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Huang R, Chen Z, He L, He N, Xi Z, Li Z, Deng Y, Zeng X. Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application. Theranostics 2017;7:3559-72. [PMID: 28912895 DOI: 10.7150/thno.20797] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
4 Toghi Eshghi S, Auger P, Mathews WR. Quality assessment and interference detection in targeted mass spectrometry data using machine learning. Clin Proteomics 2018;15:33. [PMID: 30323719 DOI: 10.1186/s12014-018-9209-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
5 Santockyte R, Zeng J, Zheng N. Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC–MS. Bioanalysis 2019;11:785-95. [DOI: 10.4155/bio-2018-0277] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ye F, Zhao Y, El-sayed R, Muhammed M, Hassan M. Advances in nanotechnology for cancer biomarkers. Nano Today 2018;18:103-23. [DOI: 10.1016/j.nantod.2017.12.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 9.3] [Reference Citation Analysis]
7 Mudduwa L, Peiris H, Gunasekara S, Abeysiriwardhana D, Liyanage N, Rayala SK, Liyanage T. KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy. BMC Cancer 2018;18:589. [PMID: 29793439 DOI: 10.1186/s12885-018-4491-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
8 Bradshaw RA, Hondermarck H, Rodriguez H. Cancer Proteomics and the Elusive Diagnostic Biomarkers. Proteomics 2019;19:e1800445. [PMID: 31172665 DOI: 10.1002/pmic.201800445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chinen AB, Guan CM, Ferrer JR, Barnaby SN, Merkel TJ, Mirkin CA. Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. Chem Rev 2015;115:10530-74. [PMID: 26313138 DOI: 10.1021/acs.chemrev.5b00321] [Cited by in Crossref: 629] [Cited by in F6Publishing: 507] [Article Influence: 89.9] [Reference Citation Analysis]
10 Jose J, Thomas AM, Mendonsa D, Al-Sanea MM, Uddin MS, Parambi DGT, Charyulu RN, Mathew B. Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle. Curr Drug Targets 2019;20:1624-35. [PMID: 31362673 DOI: 10.2174/1389450120666190729121747] [Reference Citation Analysis]
11 Rafea M, Elkafrawy P, Nasef MM, Elnemr R, Jamal AT. Applying Machine Learning of Erythrocytes Dynamic Antigens Store in Medicine. Front Mol Biosci 2019;6:19. [PMID: 31001536 DOI: 10.3389/fmolb.2019.00019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Maes E, Mertens I, Valkenborg D, Pauwels P, Rolfo C, Baggerman G. Proteomics in cancer research: Are we ready for clinical practice? Crit Rev Oncol Hematol 2015;96:437-48. [PMID: 26277237 DOI: 10.1016/j.critrevonc.2015.07.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
13 Selheim F, Aasebø E, Ribas C, Aragay AM. An Overview on G Protein-coupled Receptor-induced Signal Transduction in Acute Myeloid Leukemia. Curr Med Chem 2019;26:5293-316. [PMID: 31032748 DOI: 10.2174/0929867326666190429153247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Flashner-Abramson E, Vasudevan S, Adejumobi IA, Sonnenblick A, Kravchenko-Balasha N. Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy. Theranostics 2019;9:5149-65. [PMID: 31410207 DOI: 10.7150/thno.31657] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
15 Flepisi BT, Bouic P, Sissolak G, Rosenkranz B. Biomarkers of HIV-associated Cancer. Biomark Cancer 2014;6:11-20. [PMID: 25057241 DOI: 10.4137/BIC.S15056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
16 Samuel N, Remke M, Rutka JT, Raught B, Malkin D. Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors. J Neurooncol 2014;118:225-38. [PMID: 24771250 DOI: 10.1007/s11060-014-1432-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
17 Barbosa AI, Reis NM. A critical insight into the development pipeline of microfluidic immunoassay devices for the sensitive quantitation of protein biomarkers at the point of care. Analyst 2017;142:858-82. [PMID: 28217778 DOI: 10.1039/c6an02445a] [Cited by in Crossref: 47] [Cited by in F6Publishing: 16] [Article Influence: 11.8] [Reference Citation Analysis]
18 Gu X, Coates P, Wang L, Erdogan B, Salehi A, Sgaramella N, Zborayova K, Nylander K. Variation in Plasma Levels of TRAF2 Protein During Development of Squamous Cell Carcinoma of the Oral Tongue. Front Oncol 2021;11:753699. [PMID: 34888239 DOI: 10.3389/fonc.2021.753699] [Reference Citation Analysis]
19 Wong K, Cheung HW, Choi TLS, Kwok WH, Curl P, Mechie SC, Prabhu A, Wan TSM, Ho ENM. Label-free Proteomics for Discovering Biomarker Candidates for Controlling Krypton Misuse in Castrated Horses (Geldings). J Proteome Res 2020;19:1196-208. [DOI: 10.1021/acs.jproteome.9b00724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Nasseri B, Turk M, Kosemehmetoglu K, Kaya M, Piskin E, Rabiee N, Webster TJ. The Pimpled Gold Nanosphere: A Superior Candidate for Plasmonic Photothermal Therapy. Int J Nanomedicine 2020;15:2903-20. [PMID: 32425523 DOI: 10.2147/IJN.S248327] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
21 Walters K, Stornetta A, Jacobs F, Villalta PW, Razzoli M, Grant M, Zordoky B, Bartolomucci A, Borgatti A, Balbo S. Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients. BMC Vet Res 2021;17:378. [PMID: 34876121 DOI: 10.1186/s12917-021-03062-x] [Reference Citation Analysis]
22 Gupta P, Suman S, Mishra M, Mishra S, Srivastava N, Kumar V, Singh PK, Shukla Y. Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients. Prot Clin Appl 2016;10:564-73. [DOI: 10.1002/prca.201500138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
23 Robinson JL, Feizi A, Uhlén M, Nielsen J. A Systematic Investigation of the Malignant Functions and Diagnostic Potential of the Cancer Secretome. Cell Rep 2019;26:2622-2635.e5. [PMID: 30840886 DOI: 10.1016/j.celrep.2019.02.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
24 Totten SM, Feasley CL, Bermudez A, Pitteri SJ. Parallel Comparison of N-Linked Glycopeptide Enrichment Techniques Reveals Extensive Glycoproteomic Analysis of Plasma Enabled by SAX-ERLIC. J Proteome Res 2017;16:1249-60. [PMID: 28199111 DOI: 10.1021/acs.jproteome.6b00849] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
25 Van Keer S, Pattyn J, Tjalma WAA, Van Ostade X, Ieven M, Van Damme P, Vorsters A. First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women. Eur J Obstet Gynecol Reprod Biol 2017;216:1-11. [PMID: 28689156 DOI: 10.1016/j.ejogrb.2017.06.036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
26 Wang X, Kaczor-Urbanowicz KE, Wong DT. Salivary biomarkers in cancer detection. Med Oncol 2017;34:7. [PMID: 27943101 DOI: 10.1007/s12032-016-0863-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 51] [Article Influence: 11.7] [Reference Citation Analysis]
27 Nedelkov D. Mass spectrometry protein tests: ready for prime time (or not). Expert Review of Proteomics 2017;14:1-7. [DOI: 10.1080/14789450.2017.1256777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Percy AJ, Hardie DB, Jardim A, Yang J, Elliott MH, Zhang S, Mohammed Y, Borchers CH. Multiplexed panel of precisely quantified salivary proteins for biomarker assessment. Proteomics 2017;17. [PMID: 27538354 DOI: 10.1002/pmic.201600230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
29 Tang S, Zhang Y, Thapaliya ER, Brown AS, Wilson JN, Raymo FM. Highlighting Cancer Cells with Halochromic Switches. ACS Sens 2017;2:92-101. [DOI: 10.1021/acssensors.6b00592] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
30 Bown JL, Shovman M, Robertson P, Boiko A, Goltsov A, Mullen P, Harrison DJ. A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT. Oncotarget 2017;8:29657-67. [PMID: 27302920 DOI: 10.18632/oncotarget.8747] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Leng W, Ni X, Sun C, Lu T, Malovannaya A, Jung SY, Huang Y, Qiu Y, Sun G, Holt MV, Ding C, Sun W, Men X, Shi T, Zhu W, Wang Y, He F, Zhen B, Wang G, Qin J. Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes. EBioMedicine 2017;18:300-10. [PMID: 28396014 DOI: 10.1016/j.ebiom.2017.03.028] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
32 Zhang B, Whiteaker JR, Hoofnagle AN, Baird GS, Rodland KD, Paulovich AG. Clinical potential of mass spectrometry-based proteogenomics. Nat Rev Clin Oncol 2019;16:256-68. [PMID: 30487530 DOI: 10.1038/s41571-018-0135-7] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 22.3] [Reference Citation Analysis]
33 Farina A. Pre-fractionation of Noncirculating Biological Fluids to Improve Discovery of Clinically Relevant Protein Biomarkers. Methods Mol Biol 2019;1959:23-37. [PMID: 30852813 DOI: 10.1007/978-1-4939-9164-8_2] [Reference Citation Analysis]
34 LeBlanc A, Michaud SA, Percy AJ, Hardie DB, Yang J, Sinclair NJ, Proudfoot JI, Pistawka A, Smith DS, Borchers CH. Multiplexed MRM-Based Protein Quantitation Using Two Different Stable Isotope-Labeled Peptide Isotopologues for Calibration. J Proteome Res 2017;16:2527-36. [PMID: 28516774 DOI: 10.1021/acs.jproteome.7b00094] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
35 Frisoni GB, Jack CR, Winblad B. Alzheimer's disease biomarker development: a call to funding bodies. Neurobiology of Aging 2017;52:117-8. [DOI: 10.1016/j.neurobiolaging.2016.02.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Kisluk J, Ciborowski M, Niemira M, Kretowski A, Niklinski J. Proteomics biomarkers for non-small cell lung cancer. Journal of Pharmaceutical and Biomedical Analysis 2014;101:40-9. [DOI: 10.1016/j.jpba.2014.07.038] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
37 Mordente A, Meucci E, Martorana GE, Silvestrini A. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives. In: Scatena R, editor. Advances in Cancer Biomarkers. Dordrecht: Springer Netherlands; 2015. pp. 9-26. [DOI: 10.1007/978-94-017-7215-0_2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
38 Hernandez LI, Araúzo-Bravo MJ, Gerovska D, Solaun RR, Machado I, Balian A, Botero J, Jiménez T, Zuriarrain Bergara O, Larburu Gurruchaga L, Urruticoechea A, Hernandez FJ. Discovery and Proof-of-Concept Study of Nuclease Activity as a Novel Biomarker for Breast Cancer Tumors. Cancers (Basel) 2021;13:E276. [PMID: 33451046 DOI: 10.3390/cancers13020276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kosaka PM, Calleja M, Tamayo J. Optomechanical devices for deep plasma cancer proteomics. Semin Cancer Biol 2018;52:26-38. [PMID: 28867489 DOI: 10.1016/j.semcancer.2017.08.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
40 Bradbury M, Borràs E, Pérez-Benavente A, Gil-Moreno A, Santamaria A, Sabidó E. Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. Cancers (Basel) 2021;13:2067. [PMID: 33922979 DOI: 10.3390/cancers13092067] [Reference Citation Analysis]
41 Srivastava A, Creek DJ. Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics. Proteomics 2019;19:e1700448. [PMID: 30353665 DOI: 10.1002/pmic.201700448] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
42 Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 2016;16:525-37. [PMID: 27388699 DOI: 10.1038/nrc.2016.56] [Cited by in Crossref: 227] [Cited by in F6Publishing: 208] [Article Influence: 37.8] [Reference Citation Analysis]
43 Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, Mccabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, Mckane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants Appl Res 2018;6:1-528. [DOI: 10.3310/pgfar06030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Zinter MS, Orwoll BE, Spicer AC, Alkhouli MF, Calfee CS, Matthay MA, Sapru A. Incorporating Inflammation into Mortality Risk in Pediatric Acute Respiratory Distress Syndrome. Crit Care Med 2017;45:858-66. [PMID: 28248715 DOI: 10.1097/CCM.0000000000002370] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
45 Chang NW, Dai HJ, Shih YY, Wu CY, Dela Rosa MAC, Obena RP, Chen YJ, Hsu WL, Oyang YJ. Biomarker identification of hepatocellular carcinoma using a methodical literature mining strategy. Database (Oxford) 2017;2017:bax082. [PMID: 31725857 DOI: 10.1093/database/bax082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
46 Choi YJ, Yoon W, Lee A, Han Y, Byun Y, Kang JS, Kim H, Kwon W, Suh YA, Kim Y, Lee S, Namkung J, Han S, Choi Y, Heo JS, Park JO, Park JK, Kim SC, Kang CM, Lee WJ, Park T, Jang JY. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Ann Surg Treat Res 2021;100:144-53. [PMID: 33748028 DOI: 10.4174/astr.2021.100.3.144] [Reference Citation Analysis]
47 Combes GF, Vučković AM, Perić Bakulić M, Antoine R, Bonačić-Koutecky V, Trajković K. Nanotechnology in Tumor Biomarker Detection: The Potential of Liganded Nanoclusters as Nonlinear Optical Contrast Agents for Molecular Diagnostics of Cancer. Cancers (Basel) 2021;13:4206. [PMID: 34439360 DOI: 10.3390/cancers13164206] [Reference Citation Analysis]
48 Shi L, Zhang W, Zou F, Mei L, Wu G, Teng Y. KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma. BMC Cancer 2016;16:815. [PMID: 27769251 DOI: 10.1186/s12885-016-2851-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
49 Li Q, Kailemia MJ, Merleev AA, Xu G, Serie D, Danan LM, Haj FG, Maverakis E, Lebrilla CB. Site-Specific Glycosylation Quantitation of 50 Serum Glycoproteins Enhanced by Predictive Glycopeptidomics for Improved Disease Biomarker Discovery. Anal Chem 2019;91:5433-45. [DOI: 10.1021/acs.analchem.9b00776] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
50 Narrandes S, Xu W. Gene Expression Detection Assay for Cancer Clinical Use. J Cancer 2018;9:2249-65. [PMID: 30026820 DOI: 10.7150/jca.24744] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
51 Daughton CG. Monitoring wastewater for assessing community health: Sewage Chemical-Information Mining (SCIM). Sci Total Environ 2018;619-620:748-64. [PMID: 29161600 DOI: 10.1016/j.scitotenv.2017.11.102] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 15.4] [Reference Citation Analysis]
52 Lorenzo-Gómez R, Miranda-Castro R, de-Los-Santos-Álvarez N, Lobo-Castañón MJ. Bioanalytical methods for circulating extracellular matrix-related proteins: new opportunities in cancer diagnosis. Anal Bioanal Chem 2021. [PMID: 34091712 DOI: 10.1007/s00216-021-03416-2] [Reference Citation Analysis]
53 Li C, Ma X, Guan Y, Tang J, Zhang B. Microcantilever Array Biosensor for Simultaneous Detection of Carcinoembryonic Antigens and α-Fetoprotein Based on Real-Time Monitoring of the Profile of Cantilever. ACS Sens 2019;4:3034-41. [DOI: 10.1021/acssensors.9b01604] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
54 Martínez-García C, Medina-Flores Y, de la Rosa-Vázquez JM, Soriano-Pérez EE, Villalobos-Hernández JR, Ramón-Gallegos E. Theranostic-PDT with the antibody anti isoform 4 SOD mitocondrial labeled with PpIX in the lung cancer cell line A-549. Photodiagnosis Photodyn Ther 2018;22:197-204. [PMID: 29601905 DOI: 10.1016/j.pdpdt.2018.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Silva MLS. Lectin biosensors in cancer glycan biomarker detection. Adv Clin Chem 2019;93:1-61. [PMID: 31655728 DOI: 10.1016/bs.acc.2019.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
56 Abu Bakar N, Lefeber DJ, van Scherpenzeel M. Clinical glycomics for the diagnosis of congenital disorders of glycosylation. J Inherit Metab Dis 2018;41:499-513. [PMID: 29497882 DOI: 10.1007/s10545-018-0144-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
57 Sysel AM, Valli VE, Bauer JA. Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues. Oncotarget 2015;6:2331-48. [PMID: 25633912 DOI: 10.18632/oncotarget.3206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
58 Yotsukura S, Mamitsuka H. Evaluation of serum-based cancer biomarkers: A brief review from a clinical and computational viewpoint. Critical Reviews in Oncology/Hematology 2015;93:103-15. [DOI: 10.1016/j.critrevonc.2014.10.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
59 Lehrner A, Yehuda R. Biomarkers of PTSD: military applications and considerations. Eur J Psychotraumatol 2014;5. [PMID: 25206945 DOI: 10.3402/ejpt.v5.23797] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
60 Jafari A, Babajani A, Rezaei-Tavirani M. Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches. Biomark Insights 2021;16:11772719211013352. [PMID: 34017167 DOI: 10.1177/11772719211013352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Xiong H, Yan J, Cai S, He Q, Peng D, Liu Z, Liu Y. Cancer protein biomarker discovery based on nucleic acid aptamers. Int J Biol Macromol 2019;132:190-202. [PMID: 30926499 DOI: 10.1016/j.ijbiomac.2019.03.165] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
62 Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med 2014;3:7. [PMID: 24679154 DOI: 10.1186/2001-1326-3-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 10.6] [Reference Citation Analysis]
63 Solivio MJ, Less R, Rynes ML, Kramer M, Aksan A. Adsorbing/dissolving Lyoprotectant Matrix Technology for Non-cryogenic Storage of Archival Human Sera. Sci Rep 2016;6:24186. [PMID: 27068126 DOI: 10.1038/srep24186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Lathrop JT, Jeffery DA, Shea YR, Scholl PF, Chan MM. US Food and Drug Administration Perspectives on Clinical Mass Spectrometry. Clin Chem 2016;62:41-7. [PMID: 26553791 DOI: 10.1373/clinchem.2015.244731] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
65 DeLouize AM, Eick G, Karam SD, Snodgrass JJ. Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research. Am J Hum Biol 2021;:e23665. [PMID: 34374148 DOI: 10.1002/ajhb.23665] [Reference Citation Analysis]
66 Mayer G, Marcus K, Eisenacher M, Kohl M. Boolean modeling techniques for protein co-expression networks in systems medicine. Expert Rev Proteomics 2016;13:555-69. [PMID: 27105325 DOI: 10.1080/14789450.2016.1181546] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
67 Wang C, Senapati S, Chang HC. Liquid biopsy technologies based on membrane microfluidics: High-yield purification and selective quantification of biomarkers in nanocarriers. Electrophoresis 2020;41:1878-92. [PMID: 32180242 DOI: 10.1002/elps.202000015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Schwarz E. Identification and Clinical Translation of Biomarker Signatures: Statistical Considerations. In: Guest PC, editor. Multiplex Biomarker Techniques. New York: Springer; 2017. pp. 103-14. [DOI: 10.1007/978-1-4939-6730-8_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 Kuang Z, Huang R, Yang Z, Lv Z, Chen X, Xu F, Yi YH, Wu J, Huang RP. Quantitative screening of serum protein biomarkers by reverse phase protein arrays. Oncotarget 2018;9:32624-41. [PMID: 30220970 DOI: 10.18632/oncotarget.25976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Abou-el-naga IF, Amer EI, Boulos LM, El-faham MH, Abou Seada NM, Younis SS. Biological and proteomic studies of Schistosoma mansoni with decreased sensitivity to praziquantel. Comparative Immunology, Microbiology and Infectious Diseases 2019;66:101341. [DOI: 10.1016/j.cimid.2019.101341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
71 Bratulic S, Gatto F, Nielsen J. The Translational Status of Cancer Liquid Biopsies. Regen Eng Transl Med . [DOI: 10.1007/s40883-019-00141-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
72 Gao W, Zhang Q, Su Y, Huang P, Lu X, Gong Q, Chen W, Xu R, Tian R. Multiomic analysis of a dried single-drop plasma sample using an integrated mass spectrometry approach. Analyst 2020;145:6441-6. [PMID: 32785396 DOI: 10.1039/d0an01149e] [Reference Citation Analysis]
73 Heegaard NH, Østergaard O, Bahl JM, Overgaard M, Beck HC, Rasmussen LM, Larsen MR. Important options available--from start to finish--for translating proteomics results to clinical chemistry. Proteomics Clin Appl 2015;9:235-52. [PMID: 25472910 DOI: 10.1002/prca.201400137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
74 Lorenzo-Gómez R, Fernández-Alonso N, Miranda-Castro R, de-Los-Santos-Álvarez N, Lobo-Castañón MJ. Unravelling the lipocalin 2 interaction with aptamers: May rolling circle amplification improve their functional affinity? Talanta 2019;197:406-12. [PMID: 30771954 DOI: 10.1016/j.talanta.2019.01.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Shi Z, Wen B, Gao Q, Zhang B. Feature Selection Methods for Protein Biomarker Discovery from Proteomics or Multiomics Data. Mol Cell Proteomics 2021;20:100083. [PMID: 33887487 DOI: 10.1016/j.mcpro.2021.100083] [Reference Citation Analysis]
76 Sabbagh B, Mindt S, Neumaier M, Findeisen P. Clinical applications of MS-based protein quantification. Prot Clin Appl 2016;10:323-45. [DOI: 10.1002/prca.201500116] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
77 Brazhnik K, Sokolova Z, Baryshnikova M, Bilan R, Efimov A, Nabiev I, Sukhanova A. Quantum dot-based lab-on-a-bead system for multiplexed detection of free and total prostate-specific antigens in clinical human serum samples. Nanomedicine 2015;11:1065-75. [PMID: 25804411 DOI: 10.1016/j.nano.2015.03.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
78 Bringans S, Ito J, Casey T, Thomas S, Peters K, Crossett B, Coleman O, Ebhardt HA, Pennington SR, Lipscombe R. A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease. Clin Proteomics 2020;17:37. [PMID: 33093819 DOI: 10.1186/s12014-020-09302-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Sun J, Hu T, Chen C, Zhao D, Yang F, Yang X. Fluorescence Immunoassay System via Enzyme-Enabled in Situ Synthesis of Fluorescent Silicon Nanoparticles. Anal Chem 2016;88:9789-95. [DOI: 10.1021/acs.analchem.6b02847] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 11.7] [Reference Citation Analysis]
80 Rodrigues JG, Balmaña M, Macedo JA, Poças J, Fernandes Â, de-Freitas-Junior JCM, Pinho SS, Gomes J, Magalhães A, Gomes C, Mereiter S, Reis CA. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. Cellular Immunology 2018;333:46-57. [DOI: 10.1016/j.cellimm.2018.03.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 16.5] [Reference Citation Analysis]
81 Wu J, Chen L, Wang Y, Tan W, Huang Z. Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9,400 patients. Onco Targets Ther 2019;12:5201-13. [PMID: 31308692 DOI: 10.2147/OTT.S204403] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
82 Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018;15:617-638. [PMID: 29795272 DOI: 10.1038/s41571-018-0036-9] [Cited by in Crossref: 457] [Cited by in F6Publishing: 455] [Article Influence: 152.3] [Reference Citation Analysis]
83 Ghantasala S, Gollapalli K, Epari S, Moiyadi A, Srivastava S. Glioma tumor proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics 2020;17:221-32. [PMID: 32067544 DOI: 10.1080/14789450.2020.1731310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Wong MW, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev PS. Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. Alzheimers Dement 2017;13:810-27. [PMID: 28242299 DOI: 10.1016/j.jalz.2017.01.008] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 15.0] [Reference Citation Analysis]
85 Del Boccio P, Rossi C, di Ioia M, Cicalini I, Sacchetta P, Pieragostino D. Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine. Prot Clin Appl 2016;10:470-84. [DOI: 10.1002/prca.201500083] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
86 Pal M, Muinao T, Boruah HPD, Mahindroo N. Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges. Biomed Pharmacother 2021;146:112488. [PMID: 34894516 DOI: 10.1016/j.biopha.2021.112488] [Reference Citation Analysis]
87 Young CC, Ippolito DL. Far-Forward Diagnostics in Toxic Industrial Chemical and Material Exposure Scenarios and Biomarker Identification. J Occup Environ Med 2017;59:e204-8. [PMID: 28692011 DOI: 10.1097/JOM.0000000000001083] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
88 Borrebaeck CA. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer 2017;17:199-204. [PMID: 28154374 DOI: 10.1038/nrc.2016.153] [Cited by in Crossref: 174] [Cited by in F6Publishing: 158] [Article Influence: 34.8] [Reference Citation Analysis]
89 Vidova V, Spacil Z. A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. Analytica Chimica Acta 2017;964:7-23. [DOI: 10.1016/j.aca.2017.01.059] [Cited by in Crossref: 151] [Cited by in F6Publishing: 137] [Article Influence: 30.2] [Reference Citation Analysis]
90 Chan MK, Cooper JD, Bahn S. Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles. Trends in Biotechnology 2015;33:712-23. [DOI: 10.1016/j.tibtech.2015.09.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
91 Lourenco AP, Benson KL, Henderson MC, Silver M, Letsios E, Tran Q, Gordon KJ, Borman S, Corn C, Mulpuri R, Smith W, Alpers J, Costantini C, Rohatgi N, Yang R, Haythem A, Biren S, Morris M, Kass F, Reese DE. A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years. Clin Breast Cancer 2017;17:516-525.e6. [PMID: 28624156 DOI: 10.1016/j.clbc.2017.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
92 Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM. Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem 2015;61:809-20. [PMID: 25882892 DOI: 10.1373/clinchem.2015.239863] [Cited by in Crossref: 91] [Cited by in F6Publishing: 60] [Article Influence: 13.0] [Reference Citation Analysis]
93 Munge BS, Stracensky T, Gamez K, DiBiase D, Rusling JF. Multiplex Immunosensor Arrays for Electrochemical Detection of Cancer Biomarker Proteins. Electroanalysis 2016;28:2644-58. [PMID: 28592919 DOI: 10.1002/elan.201600183] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 9.8] [Reference Citation Analysis]
94 Hashim OH, Jayapalan JJ, Lee CS. Lectins: an effective tool for screening of potential cancer biomarkers. PeerJ. 2017;5:e3784. [PMID: 28894650 DOI: 10.7717/peerj.3784] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
95 Kim H, Sohn A, Yeo I, Yu SJ, Yoon JH, Kim Y. Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma. Clin Chem. 2018;64:1230-1238. [PMID: 29875214 DOI: 10.1373/clinchem.2018.289702] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
96 Johnsen JM, Brown DL; Members of Working Group 4, the NHLBI State of the Science Workshop on Factor VIII Inhibitors: Generating a National Blueprint for Future Research. The national blueprint for pregnancy/birth longitudinal cohorts to study factor VIII immunogenicity: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors. Haemophilia 2019;25:603-9. [PMID: 31329365 DOI: 10.1111/hae.13739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Nonaka T, Wong DTW. Saliva-Exosomics in Cancer: Molecular Characterization of Cancer-Derived Exosomes in Saliva. Enzymes 2017;42:125-51. [PMID: 29054268 DOI: 10.1016/bs.enz.2017.08.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
98 Freitas M, Nouws HP, Keating E, Delerue-matos C. High-performance electrochemical immunomagnetic assay for breast cancer analysis. Sensors and Actuators B: Chemical 2020;308:127667. [DOI: 10.1016/j.snb.2020.127667] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
99 Mattox AK, Yan H, Bettegowda C. The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors. Neuro Oncol 2019;21:1509-18. [PMID: 31595305 DOI: 10.1093/neuonc/noz156] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
100 Rodland KD. As if biomarker discovery isn't hard enough: the consequences of poorly characterized reagents. Clin Chem 2014;60:290-1. [PMID: 24305687 DOI: 10.1373/clinchem.2013.216382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
101 Torres VM, Popovic L, Vaz F, Penque D. Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications. Methods Mol Biol 2016;1395:281-98. [PMID: 26910080 DOI: 10.1007/978-1-4939-3347-1_16] [Reference Citation Analysis]
102 Percy AJ, Byrns S, Pennington SR, Holmes DT, Anderson NL, Agreste TM, Duffy MA. Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential. Expert Review of Proteomics 2016;13:673-84. [DOI: 10.1080/14789450.2016.1205950] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
103 Perzanowska A, Fatalska A, Wojtas G, Lewandowicz A, Michalak A, Krasowski G, Borchers CH, Dadlez M, Domanski D. An MRM-Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung Cancer Pleural Effusions. Prot Clin Appl 2018;12:1700084. [DOI: 10.1002/prca.201700084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
104 Bellassai N, D'Agata R, Jungbluth V, Spoto G. Surface Plasmon Resonance for Biomarker Detection: Advances in Non-invasive Cancer Diagnosis. Front Chem 2019;7:570. [PMID: 31448267 DOI: 10.3389/fchem.2019.00570] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 15.0] [Reference Citation Analysis]
105 Garcia S, Silva-Costa LC, Reis-de-Oliveira G, Guest PC, Baldasso PA, Cassoli JS, Martins-de-Souza D. Identifying Biomarker Candidates in the Blood Plasma or Serum Proteome. Adv Exp Med Biol 2017;974:193-203. [PMID: 28353236 DOI: 10.1007/978-3-319-52479-5_15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
106 Molina-Romero C, Vergara E, Arrieta O. A novel biomarker protein panel for lung cancer, a promising first step. Transl Lung Cancer Res 2018;7:S304-7. [PMID: 30705841 DOI: 10.21037/tlcr.2018.12.09] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Lahoud RM, O'Shea A, El-Mouhayyar C, Atre ID, Eurboonyanun K, Harisinghani M. Tumour markers and their utility in imaging of abdominal and pelvic malignancies. Clin Radiol 2021;76:99-107. [PMID: 32861463 DOI: 10.1016/j.crad.2020.07.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Durkin TJ, Barua B, Savagatrup S. Rapid Detection of Sepsis: Recent Advances in Biomarker Sensing Platforms. ACS Omega 2021;6:31390-5. [PMID: 34869965 DOI: 10.1021/acsomega.1c04788] [Reference Citation Analysis]
109 Mayne J, Starr AE, Ning Z, Chen R, Chiang C, Figeys D. Fine Tuning of Proteomic Technologies to Improve Biological Findings: Advancements in 2011–2013. Anal Chem 2014;86:176-95. [DOI: 10.1021/ac403551f] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
110 Ayoglu B, Schwenk JM, Nilsson P. Antigen arrays for profiling autoantibody repertoires. Bioanalysis 2016;8:1105-26. [PMID: 27097564 DOI: 10.4155/bio.16.31] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
111 Landegren U, Hammond M. Cancer diagnostics based on plasma protein biomarkers: hard times but great expectations. Mol Oncol 2021;15:1715-26. [PMID: 33012111 DOI: 10.1002/1878-0261.12809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Lin L, Yu Q, Zheng J, Cai Z, Tian R. Fast quantitative urinary proteomic profiling workflow for biomarker discovery in kidney cancer. Clin Proteomics 2018;15:42. [PMID: 30607141 DOI: 10.1186/s12014-018-9220-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
113 Gupta S, Venkatesh A, Ray S, Srivastava S. Challenges and prospects for biomarker research: a current perspective from the developing world. Biochim Biophys Acta 2014;1844:899-908. [PMID: 24412545 DOI: 10.1016/j.bbapap.2013.12.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
114 Strandberg K, Ayoglu B, Roos A, Reza M, Niks E, Signorelli M, Fasterius E, Pontén F, Lochmüller H, Domingos J, Ala P, Muntoni F, Aartsma-Rus A, Spitali P, Nilsson P, Szigyarto CA. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. J Neuromuscul Dis 2020;7:231-46. [PMID: 32390640 DOI: 10.3233/JND-190454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
115 Xue L, Lin L, Zhou W, Chen W, Tang J, Sun X, Huang P, Tian R. Mixed-mode ion exchange-based integrated proteomics technology for fast and deep plasma proteome profiling. J Chromatogr A 2018;1564:76-84. [PMID: 29935814 DOI: 10.1016/j.chroma.2018.06.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
116 Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics 2019;16:93-103. [PMID: 30556752 DOI: 10.1080/14789450.2019.1559062] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
117 Chambliss AB, Chan DW. Precision medicine: from pharmacogenomics to pharmacoproteomics. Clin Proteomics 2016;13:25. [PMID: 27708556 DOI: 10.1186/s12014-016-9127-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
118 Figueroa JM, Carter BS. Detection of glioblastoma in biofluids. Journal of Neurosurgery 2018;129:334-40. [DOI: 10.3171/2017.3.jns162280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
119 Nedelkov D. Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes. Proteomes 2017;5:E27. [PMID: 29036931 DOI: 10.3390/proteomes5040027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
120 Säll A, Corbee D, Vikström S, Ottosson F, Persson H, Waldemarson S. Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range. PLoS One 2018;13:e0189116. [PMID: 29438379 DOI: 10.1371/journal.pone.0189116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Wan-Ibrahim WI, Singh VA, Hashim OH, Abdul-Rahman PS. Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges. Mol Med 2016;21:861-72. [PMID: 26581086 DOI: 10.2119/molmed.2015.00183] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
122 Pontillo C, Filip S, Borràs DM, Mullen W, Vlahou A, Mischak H. CE-MS-based proteomics in biomarker discovery and clinical application. Prot Clin Appl 2015;9:322-34. [DOI: 10.1002/prca.201400115] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
123 Faivre S, Neuzillet C, Raymond E. Predictive Biomarkers of Response to mTOR Inhibitors. In: Mita M, Mita A, Rowinsky EK, editors. mTOR Inhibition for Cancer Therapy: Past, Present and Future. Paris: Springer; 2016. pp. 217-28. [DOI: 10.1007/978-2-8178-0492-7_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Agnifili L, Pieragostino D, Mastropasqua A, Fasanella V, Brescia L, Tosi GM, Sacchetta P, Mastropasqua L. Molecular biomarkers in primary open-angle glaucoma. New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System, Part B. Elsevier; 2015. pp. 1-32. [DOI: 10.1016/bs.pbr.2015.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
125 Thomas S, Hao L, Ricke WA, Li L. Biomarker discovery in mass spectrometry-based urinary proteomics. Proteomics Clin Appl 2016;10:358-70. [PMID: 26703953 DOI: 10.1002/prca.201500102] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 12.5] [Reference Citation Analysis]
126 Zabielska-Koczywąs K, Michalak K, Wojtalewicz A, Winiarczyk M, Adaszek Ł, Winiarczyk S, Lechowski R. Proteomic Differences in Feline Fibrosarcomas Grown Using Doxorubicin-Sensitive and -Resistant Cell Lines in the Chick Embryo Model. Int J Mol Sci 2018;19:E576. [PMID: 29443940 DOI: 10.3390/ijms19020576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
127 Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ. Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules. Clin Proteomics 2017;14:25. [PMID: 28694742 DOI: 10.1186/s12014-017-9158-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
128 Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol 2014;26:259-64. [PMID: 24626128 DOI: 10.1097/CCO.0000000000000065] [Cited by in Crossref: 103] [Cited by in F6Publishing: 58] [Article Influence: 12.9] [Reference Citation Analysis]
129 Chenab KK, Eivazzadeh-Keihan R, Maleki A, Pashazadeh-Panahi P, Hamblin MR, Mokhtarzadeh A. Biomedical applications of nanoflares: Targeted intracellular fluorescence probes. Nanomedicine 2019;17:342-58. [PMID: 30826476 DOI: 10.1016/j.nano.2019.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
130 Dhanapala L, Krause CE, Jones AL, Rusling JF. Printed Electrodes in Microfluidic Arrays for Cancer Biomarker Protein Detection. Biosensors (Basel) 2020;10:E115. [PMID: 32906644 DOI: 10.3390/bios10090115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
131 Lacombe J, Mangé A, Solassol J. Use of autoantibodies to detect the onset of breast cancer. J Immunol Res. 2014;2014:574981. [PMID: 25143958 DOI: 10.1155/2014/574981] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
132 Moisoiu V, Stefancu A, Gulei D, Boitor R, Magdo L, Raduly L, Pasca S, Kubelac P, Mehterov N, Chiș V, Simon M, Muresan M, Irimie AI, Baciut M, Stiufiuc R, Pavel IE, Achimas-Cadariu P, Ionescu C, Lazar V, Sarafian V, Notingher I, Leopold N, Berindan-Neagoe I. SERS-based differential diagnosis between multiple solid malignancies: breast, colorectal, lung, ovarian and oral cancer. Int J Nanomedicine 2019;14:6165-78. [PMID: 31447558 DOI: 10.2147/IJN.S198684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 6.3] [Reference Citation Analysis]
133 Wu L, Wang Y, Xu X, Liu Y, Lin B, Zhang M, Zhang J, Wan S, Yang C, Tan W. Aptamer-Based Detection of Circulating Targets for Precision Medicine. Chem Rev 2021. [PMID: 33667075 DOI: 10.1021/acs.chemrev.0c01140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
134 Agrawal I, Tripathi P, Biswas S. Mass Spectrometry Based Protein Biomarkers and Drug Target Discovery and Clinical Diagnosis in Age-Related Progressing Neurodegenerative Diseases. Drug Metab Rev 2022;:1-17. [PMID: 35038284 DOI: 10.1080/03602532.2022.2029475] [Reference Citation Analysis]
135 Li Q, Zhou S, Zhang T, Zheng B, Tang H. Bioinspired sensor chip for detection of miRNA-21 based on photonic crystals assisted cyclic enzymatic amplification method. Biosensors and Bioelectronics 2020;150:111866. [DOI: 10.1016/j.bios.2019.111866] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
136 Singh KD, Del Miguel GV, Gaugg MT, Ibañez AJ, Zenobi R, Kohler M, Frey U, Sinues PM. Translating secondary electrospray ionization-high-resolution mass spectrometry to the clinical environment. J Breath Res 2018;12:027113. [PMID: 29411710 DOI: 10.1088/1752-7163/aa9ee3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
137 Liu Y, Liao Y, Xiang L, Jiang K, Li S, Huangfu M, Sun S. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer. Int J Clin Oncol 2017;22:291-6. [DOI: 10.1007/s10147-016-1047-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
138 Moh ES, Thaysen-andersen M, Packer NH. Relative versus absolute quantitation in disease glycomics. Prot Clin Appl 2015;9:368-82. [DOI: 10.1002/prca.201400184] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
139 Zhao B, Gao J, Serrano MAC, Arcaro KF, Thayumanavan S, Vachet RW. Polymeric nanoassemblies for enrichment and detection of peptides and proteins in human breast milk. Anal Bioanal Chem 2020;412:1027-35. [PMID: 31925489 DOI: 10.1007/s00216-019-02342-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Yeat NC, Lin C, Sager M, Lin J. Cancer proteomics: developments in technology, clinical use and commercialization. Expert Rev Proteomics 2015;12:391-405. [PMID: 26145529 DOI: 10.1586/14789450.2015.1051969] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
141 Cantor DI, Nice EC, Baker MS. Recent findings from the human proteome project: opening the mass spectrometry toolbox to advance cancer diagnosis, surveillance and treatment. Expert Review of Proteomics 2015;12:279-93. [DOI: 10.1586/14789450.2015.1040770] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
142 Filip S, Zoidakis J, Vlahou A, Mischak H. Advances in urinary proteome analysis and applications in systems biology. Bioanalysis 2014;6:2549-69. [PMID: 25411698 DOI: 10.4155/bio.14.210] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
143 Li Z, Liu R, Lv Y. ICPMS based multiplexed bioassay: Principles, approaches and progresses. Applied Spectroscopy Reviews. [DOI: 10.1080/05704928.2021.1918703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Anaya LMB, Petitdemange R, Rosselin M, Ibarboure E, Garbay B, Garanger E, Deming TJ, Lecommandoux S. Design of Thermoresponsive Elastin-Like Glycopolypeptides for Selective Lectin Binding and Sorting. Biomacromolecules 2021;22:76-85. [PMID: 32379435 DOI: 10.1021/acs.biomac.0c00374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
145 Hanash S, Taguchi A, Wang H, Ostrin EJ. Deciphering the complexity of the cancer proteome for diagnostic applications. Expert Rev Mol Diagn 2016;16:399-405. [PMID: 26694525 DOI: 10.1586/14737159.2016.1135738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Wang J, Koo KM, Wang Y, Trau M. Engineering State-of-the-Art Plasmonic Nanomaterials for SERS-Based Clinical Liquid Biopsy Applications. Adv Sci (Weinh) 2019;6:1900730. [PMID: 31832306 DOI: 10.1002/advs.201900730] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
147 He Y, Mohamedali A, Huang C, Baker MS, Nice EC. Oncoproteomics: Current status and future opportunities. Clin Chim Acta 2019;495:611-24. [PMID: 31176645 DOI: 10.1016/j.cca.2019.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
148 Khan MU, Bowsher RR, Cameron M, Devanarayan V, Keller S, King L, Lee J, Morimoto A, Rhyne P, Stephen L, Wu Y, Wyant T, Lachno DR. Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis 2015;7:229-42. [DOI: 10.4155/bio.14.274] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
149 Li H, Bergeron S, Annis MG, Siegel PM, Juncker D. Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray. Mol Cell Proteomics 2015;14:1024-37. [PMID: 25680959 DOI: 10.1074/mcp.M114.046516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
150 Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B, Clausson CM, Zieba A, Ramström M, Söderberg O, Williams C, Asplund A. Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun 2017;8:15840. [PMID: 28643774 DOI: 10.1038/ncomms15840] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 20.4] [Reference Citation Analysis]
151 Kikuchi W, Nishimura M, Kuga T, Tsuchida S, Saito T, Satoh M, Noda K, Kodera Y, Tomonaga T, Nomura F. Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9), a biomarker for various pathological conditions, is produced in post-blood collection by fibrinolysis and coagulation factors. Clin Proteomics 2016;13:27. [PMID: 27761105 DOI: 10.1186/s12014-016-9129-6] [Reference Citation Analysis]
152 Zeidan BA, Townsend PA, Garbis SD, Copson E, Cutress RI. Clinical proteomics and breast cancer. Surgeon 2015;13:271-8. [PMID: 25736469 DOI: 10.1016/j.surge.2014.12.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
153 Chiang SF, Kan CY, Hsiao YC, Tang R, Hsieh LL, Chiang JM, Tsai WS, Yeh CY, Hsieh PS, Liang Y, Chen JS, Yu JS. Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study. Dis Markers 2015;2015:874054. [PMID: 26494939 DOI: 10.1155/2015/874054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
154 Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics. 2014;11:32. [PMID: 25114662 DOI: 10.1186/1559-0275-11-32] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
155 Endt K, Goepfert J, Omlin A, Athanasiou A, Tennstedt P, Guenther A, Rainisio M, Engeler DS, Steuber T, Gillessen S, Joos T, Schiess R. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS One 2017;12:e0181557. [PMID: 28767721 DOI: 10.1371/journal.pone.0181557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
156 Soares da Silva ML. Ferrocene‐derivative Electrochemical Probe for the Selective Detection of Carcinoma‐associated STn Antigen. Electroanalysis. [DOI: 10.1002/elan.202100352] [Reference Citation Analysis]
157 Martinez-Garcia E, Lopez-Gil C, Campoy I, Vallve J, Coll E, Cabrera S, Ramon Y Cajal S, Matias-Guiu X, Van Oostrum J, Reventos J, Gil-Moreno A, Colas E. Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteomics 2018;15:81-99. [PMID: 29183259 DOI: 10.1080/14789450.2018.1410061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
158 Chambers AG, Percy AJ, Simon R, Borchers CH. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics 2014;11:137-48. [PMID: 24476379 DOI: 10.1586/14789450.2014.877346] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
159 Quinchia J, Echeverri D, Cruz-Pacheco AF, Maldonado ME, Orozco J. Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers. Micromachines (Basel) 2020;11:E411. [PMID: 32295170 DOI: 10.3390/mi11040411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
160 Dixit CK, Kadimisetty K, Otieno BA, Tang C, Malla S, Krause CE, Rusling JF. Electrochemistry-based approaches to low cost, high sensitivity, automated, multiplexed protein immunoassays for cancer diagnostics. Analyst 2016;141:536-47. [PMID: 26525998 DOI: 10.1039/c5an01829c] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 6.1] [Reference Citation Analysis]
161 Sedighi A, Krull UJ. Enhanced Immunoassay Using a Rotating Paper Platform for Quantitative Determination of Low Abundance Protein Biomarkers. Anal Chem 2019;91:5371-9. [PMID: 30915836 DOI: 10.1021/acs.analchem.9b00502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Pool M, de Boer HR, Hooge MNL, van Vugt MATM, de Vries EGE. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics 2017;7:2111-33. [PMID: 28638489 DOI: 10.7150/thno.17934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
163 Podlesnykh SV, Kolosova EA, Shcherbakov DN, Shaidurov AA, Anisimov DS, Ryazanov MA, Johnston SA, Shoikhet YN, Petrova VD, Lazarev AF, Chapoval AI. Interaction of Serum Antibodies from Breast Cancer Patients with Synthetic Peptides. Bull Exp Biol Med 2016;161:816-20. [PMID: 27783295 DOI: 10.1007/s10517-016-3519-7] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Adeola HA, Soares NC, Paccez JD, Kaestner L, Blackburn JM, Zerbini LF. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry. Proteomics Clin Appl 2015;9:597-609. [PMID: 25708745 DOI: 10.1002/prca.201400197] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
165 Preece RL, Han SYS, Bahn S. Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders. Expert Review of Proteomics 2018;15:325-40. [DOI: 10.1080/14789450.2018.1444483] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
166 Chutipongtanate S, Chatchen S, Svasti J. Plasma prefractionation methods for proteomic analysis and perspectives in clinical applications. Prot Clin Appl 2017;11:1600135. [DOI: 10.1002/prca.201600135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
167 Mishra S, Saadat D, Kwon O, Lee Y, Choi WS, Kim JH, Yeo WH. Recent advances in salivary cancer diagnostics enabled by biosensors and bioelectronics. Biosens Bioelectron 2016;81:181-97. [PMID: 26946257 DOI: 10.1016/j.bios.2016.02.040] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
168 Azkargorta M, Soria J, Acera A, Iloro I, Elortza F. Human tear proteomics and peptidomics in ophthalmology: Toward the translation of proteomic biomarkers into clinical practice. J Proteomics 2017;150:359-67. [PMID: 27184738 DOI: 10.1016/j.jprot.2016.05.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
169 Szigyarto CA, Spitali P. Biomarkers of Duchenne muscular dystrophy: current findings. Degener Neurol Neuromuscul Dis 2018;8:1-13. [PMID: 30050384 DOI: 10.2147/DNND.S121099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
170 Domanski D, Perzanowska A, Kistowski M, Wojtas G, Michalak A, Krasowski G, Dadlez M. A Multiplexed Cytokeratin Analysis Using Targeted Mass Spectrometry Reveals Specific Profiles in Cancer-Related Pleural Effusions. Neoplasia 2016;18:399-412. [PMID: 27435923 DOI: 10.1016/j.neo.2016.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 Csősz É, Kalló G, Márkus B, Deák E, Csutak A, Tőzsér J. Quantitative body fluid proteomics in medicine - A focus on minimal invasiveness. J Proteomics 2017;153:30-43. [PMID: 27542507 DOI: 10.1016/j.jprot.2016.08.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
172 Maes E, Cho WC, Baggerman G. Translating clinical proteomics: the importance of study design. Expert Review of Proteomics 2015;12:217-9. [DOI: 10.1586/14789450.2015.1041512] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
173 Lee DH, Yoon W, Lee A, Han Y, Byun Y, Kang JS, Kim H, Kwon W, Suh YA, Choi Y, Namkung J, Han S, Yi SG, Heo JS, Han IW, Park JO, Park JK, Kim SC, Jun E, Kang CM, Lee WJ, Lee HK, Lee H, Lee S, Jeong SY, Lee KE, Han W, Park T, Jang JY. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Sci 2021. [PMID: 33991409 DOI: 10.1002/jhbp.986] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Qian T, Zhu S, Hoshida Y. Use of big data in drug development for precision medicine: an update. Expert Rev Precis Med Drug Dev. 2019;4:189-200. [PMID: 31286058 DOI: 10.1080/23808993.2019.1617632] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
175 Sun B, Hagan CT 4th, Caster J, Wang AZ. Nanotechnology in Radiation Oncology. Hematol Oncol Clin North Am 2019;33:1071-93. [PMID: 31668207 DOI: 10.1016/j.hoc.2019.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
176 Mäbert K, Cojoc M, Peitzsch C, Kurth I, Souchelnytskyi S, Dubrovska A. Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol. 2014;90:659-677. [PMID: 24524284 DOI: 10.3109/09553002.2014.892229] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 7.8] [Reference Citation Analysis]
177 Amacher DE. A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers. Biomarkers 2016;21:387-403. [PMID: 26983778 DOI: 10.3109/1354750X.2016.1153724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
178 Jin C, Qiu L, Li J, Fu T, Zhang X, Tan W. Cancer biomarker discovery using DNA aptamers. Analyst 2016;141:461-6. [PMID: 26567694 DOI: 10.1039/c5an01918d] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
179 Uzozie AC, Selevsek N, Wahlander A, Nanni P, Grossmann J, Weber A, Buffoli F, Marra G. Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis. Mol Cell Proteomics. 2017;16:407-427. [PMID: 28062797 DOI: 10.1074/mcp.m116.062273] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
180 Wang Y, Zhong X, Zhou L, Lu J, Jiang B, Liu C, Guo J. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review. Front Oncol 2020;10:1466. [PMID: 33042793 DOI: 10.3389/fonc.2020.01466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Carrigan P, Krahn T. Impact of Biomarkers on Personalized Medicine. Handb Exp Pharmacol 2016;232:285-311. [PMID: 26330258 DOI: 10.1007/164_2015_24] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
182 Wegdam W, Argmann CA, Kramer G, Vissers JP, Buist MR, Kenter GG, Aerts JM, Meijer D, Moerland PD. Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors. PLoS One 2014;9:e108046. [PMID: 25265318 DOI: 10.1371/journal.pone.0108046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
183 Zhou Y, Tan Z, Xue P, Wang Y, Li X, Guan F. High-throughput, in-depth and estimated absolute quantification of plasma proteome using data-independent acquisition/mass spectrometry ("HIAP-DIA"). Proteomics 2021;21:e2000264. [PMID: 33460299 DOI: 10.1002/pmic.202000264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Qiu X, Hildebrandt N. A clinical role for Förster resonance energy transfer in molecular diagnostics of disease. Expert Review of Molecular Diagnostics 2019;19:767-71. [DOI: 10.1080/14737159.2019.1649144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
185 Llop E, Guerrero PE, Duran A, Barrabés S, Massaguer A, Ferri MJ, Albiol-Quer M, de Llorens R, Peracaula R. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. World J Gastroenterol 2018; 24(24): 2537-2554 [PMID: 29962812 DOI: 10.3748/wjg.v24.i24.2537] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
186 Drabovich AP, Martínez-Morillo E, Diamandis EP. Toward an integrated pipeline for protein biomarker development. Biochim Biophys Acta 2015;1854:677-86. [PMID: 25218201 DOI: 10.1016/j.bbapap.2014.09.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
187 Sin DD, Hollander Z, DeMarco ML, McManus BM, Ng RT. Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation. Am J Respir Crit Care Med 2015;192:1162-70. [PMID: 26176936 DOI: 10.1164/rccm.201505-0871PP] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
188 Yonet-Tanyeri N, Ahlmark BZ, Little SR. Advances in Multiplexed Paper-Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments. Adv Mater Technol 2021;6:2001138. [PMID: 34447879 DOI: 10.1002/admt.202001138] [Reference Citation Analysis]
189 Pepe MS, Li CI, Feng Z. Improving the quality of biomarker discovery research: the right samples and enough of them. Cancer Epidemiol Biomarkers Prev 2015;24:944-50. [PMID: 25837819 DOI: 10.1158/1055-9965.EPI-14-1227] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
190 Taalberg E, Kilk K. Mapping Metabolite and ICD-10 Associations. Metabolites 2020;10:E196. [PMID: 32423141 DOI: 10.3390/metabo10050196] [Reference Citation Analysis]
191 Lorentzian A, Uzozie A, Lange PF. Origins and clinical relevance of proteoforms in pediatric malignancies. Expert Rev Proteomics 2019;16:185-200. [PMID: 30700156 DOI: 10.1080/14789450.2019.1575206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
192 Cheng J, Nonaka T, Ye Q, Wei F, Wong DTW. Salivaomics, Saliva-Exosomics, and Saliva Liquid Biopsy. In: Granger DA, Taylor MK, editors. Salivary Bioscience. Cham: Springer International Publishing; 2020. pp. 157-75. [DOI: 10.1007/978-3-030-35784-9_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Sobsey CA, Ibrahim S, Richard VR, Gaspar V, Mitsa G, Lacasse V, Zahedi RP, Batist G, Borchers CH. Targeted and Untargeted Proteomics Approaches in Biomarker Development. Proteomics 2020;20:1900029. [DOI: 10.1002/pmic.201900029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
194 Bertok T, Lorencova L, Chocholova E, Jane E, Vikartovska A, Kasak P, Tkac J. Electrochemical Impedance Spectroscopy Based Biosensors: Mechanistic Principles, Analytical Examples and Challenges towards Commercialization for Assays of Protein Cancer Biomarkers. ChemElectroChem 2019;6:989-1003. [DOI: 10.1002/celc.201800848] [Cited by in Crossref: 55] [Cited by in F6Publishing: 17] [Article Influence: 13.8] [Reference Citation Analysis]
195 Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. Clin Pharmacol Ther 2015;98:34-46. [PMID: 25868461 DOI: 10.1002/cpt.136] [Cited by in Crossref: 119] [Cited by in F6Publishing: 100] [Article Influence: 17.0] [Reference Citation Analysis]
196 Smith JN, Tyrrell KJ, Hansen JR, Thomas DG, Murphree TA, Shukla A, Luders T, Madden JM, Li Y, Wright AT, Piehowski PD. Plasma Protein Turnover Rates in Rats Using Stable Isotope Labeling, Global Proteomics, and Activity-Based Protein Profiling. Anal Chem 2017;89:13559-66. [PMID: 29164873 DOI: 10.1021/acs.analchem.7b03984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
197 Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics 2016;13:1. [PMID: 26751220 DOI: 10.1186/s12014-015-9102-9] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 23.8] [Reference Citation Analysis]
198 Das P, Sedighi A, Krull UJ. Cancer biomarker determination by resonance energy transfer using functional fluorescent nanoprobes. Analytica Chimica Acta 2018;1041:1-24. [DOI: 10.1016/j.aca.2018.07.060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
199 Zhou C, Zhong X, Song Y, Shi J, Wu Z, Guo Z, Sun J, Wang Z. Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence. Front Oncol 2019;9:1321. [PMID: 31850212 DOI: 10.3389/fonc.2019.01321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
200 Logun M, Zhao W, Mao L, Karumbaiah L. Microfluidics in Malignant Glioma Research and Precision Medicine. Adv Biosyst 2018;2:1700221. [PMID: 29780878 DOI: 10.1002/adbi.201700221] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
201 Silva MLS. Microfluidic devices for glycobiomarker detection in cancer. Clin Chim Acta 2021;521:229-43. [PMID: 34273337 DOI: 10.1016/j.cca.2021.07.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
202 Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP. Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol. 2015;181:635-647. [PMID: 25792606 DOI: 10.1093/aje/kwu462] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
203 Zhang Y, Zhang L, Iliuk A, Tao WA. Profiling Glycoproteins on Functionalized Reverse Phase Protein Array. Methods Mol Biol 2021;2237:207-15. [PMID: 33237420 DOI: 10.1007/978-1-0716-1064-0_17] [Reference Citation Analysis]
204 Li S, Thomas SN, Yang S. Glycoprotein Biomarkers. In: Weng N, Jian W, editors. Targeted Biomarker Quantitation by LC-MS. Hoboken: John Wiley & Sons, Inc.; 2017. pp. 245-72. [DOI: 10.1002/9781119413073.ch16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
205 Al-Khalili Szigyarto C. Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application. Expert Rev Proteomics 2020;17:365-75. [PMID: 32713262 DOI: 10.1080/14789450.2020.1773806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
206 O’Hurley G, Sjöstedt E, Rahman A, Li B, Kampf C, Pontén F, Gallagher WM, Lindskog C. Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol. 2014;8:783-798. [PMID: 24725481 DOI: 10.1016/j.molonc.2014.03.008] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 10.8] [Reference Citation Analysis]
207 Devillers M, Ahmad L, Korri-youssoufi H, Salmon L. Carbohydrate-based electrochemical biosensor for detection of a cancer biomarker in human plasma. Biosensors and Bioelectronics 2017;96:178-85. [DOI: 10.1016/j.bios.2017.04.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
208 Ménoret A, Crocker SJ, Rodriguez A, Rathinam VA, Clark RB, Vella AT. Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform. Proteomics Clin Appl 2016;10:8-24. [PMID: 26201056 DOI: 10.1002/prca.201500029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
209 Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays. Mol Oncol. 2014;8:840-858. [PMID: 24713096 DOI: 10.1016/j.molonc.2014.03.006] [Cited by in Crossref: 139] [Cited by in F6Publishing: 126] [Article Influence: 17.4] [Reference Citation Analysis]
210 Percy AJ, Mohammed Y, Yang J, Borchers CH. A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma. Bioanalysis 2015;7:2991-3004. [DOI: 10.4155/bio.15.222] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
211 Terävä J, Verhassel A, Botti O, Islam MK, Leivo J, Wittfooth S, Härkönen P, Pettersson K, Gidwani K. Primary breast cancer biomarkers based on glycosylation and extracellular vesicles detected from human serum. Cancer Rep (Hoboken) 2021;:e1540. [PMID: 34423573 DOI: 10.1002/cnr2.1540] [Reference Citation Analysis]
212 Jeyapala R, Kamdar S, Olkhov-mitsel E, Zlotta A, Fleshner N, Visakorpi T, van der Kwast T, Bapat B. Combining CAPRA-S with tumor IDC/C features improves the prognostication of biochemical recurrence in prostate cancer patients. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.01.003] [Reference Citation Analysis]
213 Lastovickova M, Strouhalova D, Bobalova J. Use of Lectin-based Affinity Techniques in Breast Cancer Glycoproteomics: A Review. J Proteome Res 2020;19:1885-99. [PMID: 32181666 DOI: 10.1021/acs.jproteome.9b00818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
214 Shehzad A, Islam SU, Shahzad R, Khan S, Lee YS. Extracellular vesicles in cancer diagnostics and therapeutics. Pharmacol Ther 2021;223:107806. [PMID: 33465400 DOI: 10.1016/j.pharmthera.2021.107806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
215 van der Watt PJ, Okpara MO, Wishart A, Parker MI, Soares NC, Blackburn JM, Leaner VD. Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkers. Int J Cancer 2021. [PMID: 34591985 DOI: 10.1002/ijc.33832] [Reference Citation Analysis]
216 Popp R, Basik M, Spatz A, Batist G, Zahedi RP, Borchers CH. How iMALDI can improve clinical diagnostics. Analyst 2018;143:2197-203. [DOI: 10.1039/c8an00094h] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]